the wake of Madras High Court''s decision against Novartis'' plea for a review of
the Indian patent laws Multinational drug makers may hold back their product launches
a spate of anti-cancer drug launches last year, multinational drug companies may
go slow in launching their products in India.
year, Swiss drug maker Roche launched anti-cancer drugs Mabthera and Tarceva while
Merck of Germany launched Erbitux to treat colorectal cancer. These are established
blockbuster brands for multinational drug makers.
following the Madras high court''s decision dismissing Novartis'' plea for a review
of certain provisions of the Indian patent law, a few companies may go slow on
for one may go slow on its overall investments in India. The company may not immediately
bring into India its anti-asthma drug Xolair.
also indicated that Pfizer had supported Novartis'' stand on patenting of incremental
innovation and may not be keen to take up launch of patented products immediately.
feel many Indian companies like Nicholas Piramal are working on incremental innovations
and the rejection of product patent to Novartis'' Glivec may jeopardise their research